Abstract
A series of 4-alkoxychalcones
(1
–
12)
has been evaluated for their in vitro antiglycation activity. Compound
2
(IC
50
= 89.07 ± 1.3 μM), compound
3
(IC
50
= 266.82 ± 4.6 μM), and compound
5
(IC
50
= 285.79 ± 1.9 μM) showed an excellent antiglycation potential better than the standard (rutin, IC
50
= 294.50 ± 1.5 μM). Additionally, all the compounds of this series were evaluated for their cytotoxicity against
Artemia salina
(brine shrimp) and one tumor cell line, namely human Prostate Cancer cell line (PC-3). All the compounds showed low toxicity against brine shrimp with LD
50
values much lower than the standard etoposide. Similarly, a much lower toxicity was observed for all the compounds against PC-3 cell line compared to doxorubicin, a standard reference drug used for this study. The molecular docking studies were also carried out to support the experimental results. A good correlation was found between experimental and theoretical results. The compounds of this series are therefore excellent antiglycating agents with no or very little cytotoxicity and represent a new class of antiglycating agents that deserve to be focused on for further research and in vivo studies in the future.